The concentrations of ceftazidime in the serum and cerebrospinal fluid of patients with and without meningitis were measured at various times after a 2-or 3-g dose. At similar concentrations in serum, ceftazidime concentrations in cerebrospinal fluid at a given time were substantially lower in patients without meningitis (mean, 0.8 ,ug/ml) than in those with meningitis (mean, 22.6 ,ig/ml). 
The high activity of ceftazidime in vitro against most members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and most bacteria causing meningitis, as well as its bactericidal properties and stability to a wide range of beta-lactamases (4, 5) , recommends this cephalosporin for treatment of gram-negative meningitis. One Lumbar punctures or ventricular reservoir aspiration was performed 2 to 3 or 6 to 7 h after the infusion.
Ceftazidime assay. Ceftazidime concentrations in CSF and serum were measured by high-pressure liquid chromatography by Glaxo Canada Ltd., using a modification of the method of Myers and Blumer (3), and are shown in Table 1 .
Drug concentrations in the CSF of patients with noninflamed meninges ranged from 0 to 1.8 [xg of ceftazidime per ml (mean, 0.8 p.g/ml) at 2 to 3 h postdose. In patients with aseptic meningitis, peak levels of ceftazidime in CSF ranged from 1.8 to 35.4 p.g/ml (mean, 12.6 ,ug/ml). However, the patient with the highest level had significant blood contamination, and, with exclusion of this result, the mean level in CSF was 6.9 ,ug/ml, 18% of the concomitant serum level. Ceftazidime peak levels in CSF in group III ranged from 2.7 to 56 ,ug/ml (mean, 22.6 ,ug/ml), with an average penetration of 45% of the concomitant serum level. The mean peak ceftazidime level in CSF of group III patients was significantly higher than the corrected mean level of group II patients (6.9 ,ug/ml); P = 0.01 by Student's t test. Trough CSF levels at 6 to 7 h postinfusion ranged from 10.5 to 36.7 ,ug/ml (mean, 21 ,ug/ml). Although ceftazidime levels in CSF clearly varied with the presence or absence of meningeal inflammation, there was no linear correlation with CSF penetration and degree of pleocytosis or protein concentration.
These results show that ceftazidime penetrates the inflamed meninges much better than the noninflamed meninges, a feature of other beta-lactam antibiotics (1). The ceftazidime peak level in CSF was higher in group III patients (22.6 ,ug/ml) than in group II patients (6.9 ,ug/ml). These differences could be accounted for by difference in drug administration, multiple doses versus single dose of ceftazidime, and degree of meningeal inflammation. High trough levels at 6 to 7 h postinfusion were seen in all patients with inflamed meninges, suggesting accumulation in the CSF, probably due to decreased clearance from the subarachnoid space.
Modai et al. (2) also reported good penetration of ceftazidime in patients with bacterial meningitis, with CSF levels varying from 2 to 30 pLg/ml, depending on the sampling time and the time elapsed since onset of disease. The latter observation probably reflects variation in meningeal inflammation.
The levels of ceftazidime in CSF are severalfold the reported MICs of most bacteria causing meningitis. Hence, ANTIMICROB. AGENTS CHEMOTHER. this should be a useful agent in the treatment of the majority of cases of bacterial meningitis.
